GENE ONLINE|News &
Opinion
Blog

2021-06-23| Asia-Pacific

Alibaba Health, Berry Oncology Expand Scale of Early Cancer Detection in China

by Tyler Chen
Share To

Cancer has been one of China’s biggest challenges in healthcare. According to statistics, cancer patients in the country are expected to reach around 5.7 million by 2030. To address this issue, China released the Healthy China 2030 plan in 2016, hoping to increase the overall five-year survival rate by 15% and expand the cover rate of early cancer detection in high-risk areas to 55% by 2030.

As part of the solution, Alibaba Health, on June 21st, shook hands with Berry Oncology and established the groundwork for building an ecosystem to facilitate early cancer diagnosis.

 

Deliver NGS Liver Cancer Tests to High-Risk Areas

Alibaba Health will help deliver Berry Oncology’s NGS-based liver cancer test, Lai Si Ning, to people in high-risk areas. According to a Cell Research publication, the test has a specificity of 95.7% and a sensitivity of 95.7%. Besides, it can detect liver cancer 6 to 12 months earlier.

The tool can also be purchased on Alibaba’s e-commerce platform so that everyone can get easy access to early cancer detection. Patients can also receive China’s first hepatopathy medical insurance and consultant services with early cancer test products.

“Alibaba Health and Berry Oncology have unique advantages in their respective fields, and this partnership will bring results greater than the sum of its parts,” said Zhou Jun, CEO of Berry Oncology

“For Berry Oncology, the establishment of a Chinese program for early cancer screening and prevention must integrate all aspects of the business, including commerce, clinical work, technology, and the industrial chain,” he added.

 

Early Cancer Screening

Berry Oncology, founded in 2017, is a subsidiary of Berry Genomics, a genetic testing firm in China. It currently focuses on three types of cancers; liver cancer, lung cancer, and gynecologic cancer. Furthermore, it has manufacturing, supercomputing, and R & D centers in Fuzhou and Beijing.

In 2021, the firm teamed up with Twist Bioscience to develop NGS products to screen cancer and genetic diseases.

Related Article: Chinese Oncology Drugmaker to Raise over 600 Million in Hong Kong IPO

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Targeting Metabolism for Noninvasive Multi-Cancer Early Detection Tests
2022-12-08
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
R&D
Senescent Cancer Cells Vaccine Boost Immune Response
2022-11-07
LATEST
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
2023-03-19
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Amgen Faces Class Action Lawsuit for Concealing $10.7 Billion Tax Bill to Manipulate Stock Price
2023-03-16
ImmunoPrecise Antibodies, Libera Bio Ink $155 Million Pact To Deliver Antibodies With Nanotechnology
2023-03-16
Dermavant Eyes Second Vtama Indication with Topline Atopic Dermatitis Results
2023-03-15
Scroll to Top